APLS - Phase 3 data shows Apellis blood disorder drug besting Alexion's Soliris

Full phase 3 data for Apellis Pharmaceuticals' (APLS) paroxysmal nocturnal hemoglobinuria (PNH) drug candidate pegcetacoplan indicates it is superior to Alexion Pharmaceuticals' (ALXN) Soliris (eculizumab).The data was published in The New England Journal of Medicine.Full results from the PEGASUS study showed that pegcetacoplan met its primary endpoint, superiority to Soliris, with a statistically significant improvement in adjusted means of 3.8 g/dL of hemoglobin at week 16.Also 85% of patients that received pegcetacoplan did not need transfusions over 16 weeks compared to 15% of Soliris-treated patients.Safety was similar across the two treatments.Top-line results from the PEGASUS study were presented in December.Pegcetacoplan has been granted FDA Priority Review status with a PDUFA date of May 14, 2021.Apellis is partnered with Swedish Orphan Biovitrum AB (BIOVF) on pegcetacoplan.PNH is a rare, chronic, life-threatening blood disorder characterized by the destruction of oxygen-carrying red blood cells through extravascular and intravascular hemolysis.Apellis shares are up 2.3% to $27.01 in yesterday's

For further details see:

Phase 3 data shows Apellis blood disorder drug besting Alexion's Soliris